Proactive Investors
15 Jul 2026, 19:35 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Johnson & Johnson reported Q2 worldwide sales of $584 million for Spravato, a 25% increase from the previous quarter. — Strong commercial performance of a key esketamine product validates the market demand and reimbursement pathways for psychedelic-based mental health treatments.
+0.60Jefferies analysts state that Spravato's success supports the commercial viability of the broader psychedelic sector for hard-to-treat mental health disorders. — This provides a positive 'read-through' for smaller developers like AtaiBeckley, Compass Pathways, and Cybin by reducing perceived commercial risk.
+0.50Compass Pathways plans to complete a rolling New Drug Application for COMP360 in Q4 2026, targeting a potential approval by year-end. — This represents a concrete, near-term regulatory catalyst that could lead to a commercial launch in early 2027.
+0.40Continue reading
6 related stories
Top 2 movers · tap to explore
Johnson & Johnson has guided for Spravato peak annual sales of up to $5 billion. — High peak sales guidance signals a massive addressable market for the category, though it is a long-term projection.
+0.30Which stocks this story touches
Reported strong second-quarter sales for Spravato, showing 25% growth and progress toward annual targets.
The company is seeing a positive read-through from J&J's Spravato sales and has upcoming clinical milestones.
Positive sector outlook and an upcoming NDA completion for COMP360 provide growth potential.
The company is listed as a beneficiary of the positive commercial performance of Spravato in the psychedelics sector.
[mutual] Both are psychedelic drug developers competing in the mental health disorder market.
[mutual] Both are psychedelic drug developers competing in the mental health disorder market.
[mutual] Both are psychedelic drug developers competing in the mental health disorder market.
[mutual] JNJ's Spravato competes for the same treatment-resistant depression market as ATAI's BPL-003.
[mutual] JNJ's Spravato competes for the same treatment-resistant depression market as CMPS's COMP360.
[mutual] JNJ's Spravato competes for the same treatment-resistant depression market as CYBN's psychedelic therapies.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
3h ago
